Vafidemstat

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 572153

CAS#: 1357362-02-7

Description: Vafidemstat, also known as ORY 2001, is a lysine-specific histone demethylase (LSD1) inhibitor. Studies have shown LSD1 inhibitors to be effective in cancer suppression (i.e. breast and prostate cancer) as well as endometriosis.


Chemical Structure

img
Vafidemstat
CAS# 1357362-02-7

Theoretical Analysis

MedKoo Cat#: 572153
Name: Vafidemstat
CAS#: 1357362-02-7
Chemical Formula: C19H20N4O2
Exact Mass: 336.1586
Molecular Weight: 336.4
Elemental Analysis: C, 67.84; H, 5.99; N, 16.66; O, 9.51

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ORY 2001; ORY-2001; ORY2001; Vafidemstat;

IUPAC/Chemical Name: 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine

InChi Key: XBBRLCXCBCZIOI-DLBZAZTESA-N

InChi Code: InChI=1S/C19H20N4O2/c20-19-23-22-18(25-19)11-21-17-10-16(17)14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16-17,21H,10-12H2,(H2,20,23)/t16-,17+/m0/s1

SMILES Code: [H][C@@]1([C@@](NCC2=NN=C(N)O2)([H])C1)C(C=C3)=CC=C3OCC4=CC=CC=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 336.4 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hayward D, Cole PA. LSD1 Histone Demethylase Assays and Inhibition. Methods Enzymol. 2016;573:261-78. doi: 10.1016/bs.mie.2016.01.020. Epub 2016 Feb 23. Review. PubMed PMID: 27372757; PubMed Central PMCID: PMC5178825.

2: Sun Q, Ding D, Liu X, Guo SW. Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Reprod Biol Endocrinol. 2016 Apr 9;14:17. doi: 10.1186/s12958-016-0154-0. PubMed PMID: 27062244; PubMed Central PMCID: PMC4826530.

3: Etani T, Suzuki T, Naiki T, Naiki-Ito A, Ando R, Iida K, Kawai N, Tozawa K, Miyata N, Kohri K, Takahashi S. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect. Oncotarget. 2015 Feb 20;6(5):2865-78. PubMed PMID: 25605246; PubMed Central PMCID: PMC4413623.

4: Mino K, Nishimura S, Ninomiya S, Tujii H, Matsumori Y, Tsuchida M, Hosoi M, Koseki K, Wada S, Hasegawa M, Sasaki R, Murakami-Yamaguchi Y, Narita H, Suzuki T, Miyata N, Mizukami T. Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2). Biosci Biotechnol Biochem. 2014;78(6):1010-7. doi: 10.1080/09168451.2014.910104. Epub 2014 Jun 13. PubMed PMID: 25036127.

5: Murray-Stewart T, Woster PM, Casero RA Jr. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. Amino Acids. 2014 Mar;46(3):585-94. doi: 10.1007/s00726-013-1485-1. Epub 2013 Mar 19. PubMed PMID: 23508577; PubMed Central PMCID: PMC3692581.

6: Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis. 2013 Jun;34(6):1196-207. doi: 10.1093/carcin/bgt033. Epub 2013 Jan 25. PubMed PMID: 23354309; PubMed Central PMCID: PMC3670252.

7: Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W, Jung M, Forne I, Imhof A, Janzer A, Kirfel J, Waldmann H, Schüle R, Buettner R. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer. 2012 Dec 1;131(11):2704-9. doi: 10.1002/ijc.27555. Epub 2012 Jun 28. PubMed PMID: 22447389.